Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic AnemiaOncology Published on 2020-09-182022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] acute respiratory syndrome Anemia antibody Aplastic anemia coronavirus COVID-19 Cytokine storm develop discharged elevated Fever hospital immunodeficiency Infection inflammatory conditions inflammatory markers interleukin-6 receptor manifested Patient pulmonary infiltrates resolved SARS-CoV-2 severe coronavirus disease severe hypoxia the patient therapy Tocilizumab Treatment treatment approach treatment with tocilizumab while [DOI] 10.3389/fonc.2020.562625 PMC 바로가기 [Article Type] Oncology
Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in MadridOncology Published on 2020-09-162022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] abnormality acute respiratory distress Admission affected Anti-viral treatment anticoagulation ARDS baseline cancer patient cancer treatment conditions coronavirus Corticosteroids cough COVID-19 COVID-19 illness D-dimer diagnosed with COVID-19 Diagnosis discharged elevated Fever fibrinogen first positive high mortality rate high variability hospital Hospitalization hospitalized patient Hydroxychloroquine Immunotherapy incidence inflammation marker Inflammatory invasive lab lung cancer lung cancer patient lung cancer patients lymphocyte measure Mortality Multiple multivariate multivariate model neutrophil no difference outcome pandemic Patient patients PCR Pneumonia PROTECT Protein receiving risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 RT-PCR Shortness of breath Spain statistically significant symptoms onset syndrome targeted therapy Tertiary therapy Thoracic time Tocilizumab Treatment variable [DOI] 10.3389/fonc.2020.01777 PMC 바로가기 [Article Type] Oncology
COVID-19 Presenting as Lupus Erythematosus-Like Syndrome홍반성 루푸스 유사 증후군으로 나타나는 COVID-19Case Reports Published on 2020-09-102022-09-12 Journal: Disaster Medicine and Public Health Preparedness [Category] MERS, 진단, [키워드] 2019 coronavirus disease Acute kidney injury COVID-19 COVID-19 patient described feature glucocorticoid Infection Lupus lupus-like symptoms mimicking Multiorgan multiorgan damages Other predominant presenting Respiratory complications systemic lupus erythematosus Tocilizumab treated [DOI] 10.1017/dmp.2020.358 PMC 바로가기 [Article Type] Case Reports
Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumoniaSARS-CoV-2 폐렴에 대한 면역억제 치료 중 나타난 Strongyloides 감염Case Reports Published on 2020-09-102022-09-12 Journal: Infection [Category] MERS, SARS, 진단, [키워드] abdominal pain bilateral pneumonia Complication Corticosteroid Corticosteroids Course cytokine cytokine inhibitor cytokine inhibitors Dexamethasone eosinophil Eosinophil count Evidence full recovery High dose High-dose Hyperinflammatory Immunosuppression immunosuppressive Immunosuppressive agents immunosuppressive therapy Infection infections interstitial intravenous intravenous dose involved Italian itching Ivermectin Latent infections manifested Pathogenesis Patient Pneumonia public health Reactivation risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2 pneumonia severe COVID-19 severe disease steroid Steroids Stool examination Strongyloides stercoralis strongyloidiasis suggested therapy Tocilizumab treated Treatment [DOI] 10.1007/s15010-020-01522-4 PMC 바로가기 [Article Type] Case Reports
COVID-19 therapy and preventionReview Article Published on 2020-09-102022-11-01 Journal: Discoveries [Category] COVID-19, [키워드] activities antimicrobial agent caused Chloroquine collected Combination comparison coronavirus COVID-19 Dexamethasone diagnosed disease effective Efficacy effort epidemiological Evidence Evolution Favipiravir Government Hydroxychloroquine immunomodulators information interferon Mask measure New coronavirus other coronaviruses outbreak Outbreaks pandemic Perspective Pneumonia provide provided question raised Remdesivir Respirator SARS-CoV-2 SARS-CoV-2 remdesivir similarity starting point Support the mean therapeutic Therapies therapy Tocilizumab Transmissibility Vaccine Vaccines virus [DOI] 10.15190/d.2020.10 PMC 바로가기 [Article Type] Review Article
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome530 Published on 2020-09-082022-10-29 Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, MERS, SARS, [키워드] accompanied Activation acute respiratory distress ARDS Bacteria Bacterial Bacterial infection Bacterial sepsis blockade Burn causes chimeric antigen receptor Clinical efficacy clinical manifestation coagulation cascade COVID-19 COVID-19 patient Critical CRS cytokine cytokine production Cytokine release syndrome diagnosed dysfunction elevated endothelial Endothelial cell Endothelial dysfunction endotheliopathy exhibited highlight Human monoclonal antibody Hyperinflammatory hyperinflammatory responses IL-10 IL-6 IL-6 signaling IL-8 Immunotherapy in vitro data indicate induce infections Inflammation involved life-threatening MCP-1 molecular mechanism monocyte chemotactic protein-1 Pathogenesis Patient Proinflammatory cytokine promoted robust Sepsis severe COVID-19 patient severe COVID-19 patients Signaling Significance syndrome systemic inflammatory response T cell therapy Tocilizumab trans-signaling Treatment vascular endothelial cell [DOI] 10.1073/pnas.2010229117 PMC 바로가기 [Article Type] 530
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-09-032022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 1:1 48 hours absence Admission all-cause mortality Arm blinded chest imaging clinical commenced Confirmed COVID-19 criteria CRP D-dimer Data analysis database death defined demonstrated determine disease dissemination dose Efficacy element eligible participant enrolled EudraCT Evidence evidence of evidenced facilitate ferritin fibrinogen hospital humanized monoclonal antibody hyper-inflammation IL-6 IL6 immunology independent Infection inflammatory state infused inhibit interleukin-6 intravenous tocilizumab intubation investigators Ireland LDH low dose management Mater moderate to severe multicentre non-invasive ventilation number objective Older open label outcome PaO participant Patient patients with COVID-19 PCR-confirmed COVID-19 performed positive PCR Potential treatment primary endpoint Primary outcome progression protocol pulmonary randomisation randomised randomised controlled trial Randomised trial receive recruited reduced Registered reported Respiratory failure Respiratory function Sample size SARS-CoV2 infection single dose Stage stage 2 Standard Standard dose status Study protocol subject subjects subsequent systemic inflammation target temperature Therapeutics Tocilizumab treatment group Trial ULN university Ventilation website [DOI] 10.1186/s13063-020-04680-w PMC 바로가기 [Article Type] Letter
A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress SyndromeCOVID-19 급성 호흡곤란 증후군에서 토실리주맙에 대한 종합적인 검토Review Published on 2020-09-012022-09-12 Journal: Journal of clinical pharmacology [Category] 진단, [키워드] 2019 coronavirus disease acute lung injury acute respiratory syndrome ARDS beta-coronavirus Comprehensive coronavirus COVID-19 CRS cytokine-release syndrome distress Evidence IL-6 indicated lung management monoclonal antibody pandemic pathophysiology patients with COVID-19 respiratory review SARS-CoV-2 syndrome the disease therapeutic therapy Tocilizumab Treatment [DOI] 10.1002/jcph.1693 PMC 바로가기 [Article Type] Review
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talkingReview article Published on 2020-09-012022-10-05 Journal: Virus research [Category] SARS, 비임상, 치료제, [키워드] amplification Anakinra Baricitinib clinical trial Coagulation Coagulopathy coronavirus Corticosteroid COVID-19 Cytokine storm Dexamethasone drug drugs eculizumab emapalumab heparin Human implicated include Infection Inflammation inflammatory phase Lopinavir/ritonavir mild infection Remdesivir response responsible review ruxolitinib SARS-CoV-1 SARS-CoV-2 Severe case severe cases suggested therapeutic option Therapies therapy Tocilizumab Treatment [DOI] 10.1016/j.virusres.2020.198070 [Article Type] Review article
Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19Comment Published on 2020-09-012023-07-14 Journal: Travel medicine and infectious disease [Category] SARS, [키워드] coronavirus COVID-19 IL-6 SARS-CoV-2 Tocilizumab [DOI] 10.1016/j.tmaid.2020.101678 PMC 바로가기 [Article Type] Comment